Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The 8th International Conference on Protein Kinase CK2 (www.uks.eu/ck2), organized by Matthias Montenarh and Claudia Götz, will be held at the Faculty of Medicine of Saarland University, in Homburg, Germany, from 6-9 September, 2016. Protein kinase CK2 is a serine/threonine kinase, which is highly conserved in evolution. Knock-out experiments have shown that this enzyme is absolutely necessary for cell viability. The enzyme is highly expressed in rapidly proliferating cells, which goes along with an elevated enzyme activity. Protein kinase CK2 is involved in a broad range of signaling pathways, regulating proliferation, differentiation, apoptosis, or senescence. Recent advances towards the characterization of the three-dimensional structure of protein kinase CK2 and its subunits will undoubtedly yield important new insights into its regulation, and the functions of CK2. Moreover, with two inhibitors of the enzyme presently in clinical phase II trials, human protein kinase CK2 has appeared as an emerging target for cancer diseases.

Protein kinase CK2.

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Protein Kinase Inhibitors: From Discovery to Therapeutics offers a foundational, pragmatic overview of protein kinases inhibitors and their potential role in disease modulation and treatment. Here, international experts in the field offer an integrated discussion of kinase inhibitor biology, biomarker discovery, and methods for drug design and development. After a brief overview of kinases and kinase inhibitors, subsequent chapters discuss individual kinases that are representative of the wider kinases and kinase families, including their roles in disease pathogenesis, underlying mechanisms, potential inhibitors and their modes of action for therapeutic modulation. Several potential drugs under different stages of clinical trials are discussed, including their relevance to cancer, diabetes, obesity, cardiovascular, neurological, and auto-immune and inflammatory disease, among other disorders. The book also addresses the challenges and opportunities for future kinase inhibitor development.

Protein kinases --- Protein kinases. --- Inhibitors. --- Protein kinase --- Protein phosphotransferases --- Phosphotransferases --- Kinase inhibitors --- Protein kinase inhibitors --- Enzyme inhibitors --- Protein Kinase Inhibitors

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Protein kinases. --- Protein kinase --- Protein phosphotransferases --- Phosphotransferases

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Proteins are the work horses of the cell. As regulators of protein function, protein kinases are involved in the control of cellular functions via intricate signalling pathways, allowing for fine tuning of physiological functions. This book is a collaborative effort, with contribution from experts in their respective fields, reflecting the spirit of collaboration - across disciplines and borders - that exists in modern science. Here, we review the existing literature and, on occasions, provide novel data on the function of protein kinases in various systems. We also discuss the implications of these findings in the context of disease, treatment, and drug development.

Protein kinases. --- Protein kinase --- Protein phosphotransferases --- Phosphotransferases --- Enzymology

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Ce travail a pour objectif de mettre en évidence les différentes interactions médicamenteuses rencontrées lors de la prise d'inhibiteurs de tyrosine kinase (lTKs) chez des patients atteints de tumeurs hématologiques. Il se limite à l’étude de quatre médicaments : le dasatinib, l'ibrutinib, l'imatinib et le nilotinib. L'étude des différentes sources potentielles d'interactions se fera d'une part par une recherche bibliographique et d'autre part par une analyse de dossiers de patients traités par ces ITKs aux Cliniques universitaires Saint-Luc. Enfin, les informations récoltées seront rassemblées dans un outil concret et utile pour aider les prescripteurs à gérer les interactions médicamenteuses avec les JTKs. The aim of this thesis is to highlight the different drug-drug interactions involved in the use of tyrosine kinase inhibitors (TKIs) among patients with hematologic malignancies. We’ll therefore be focusing on four drugs: dasatinib, ibrutinib, imatinib and nilotinib. The informations about the different potential sources of interactions will first be collected through literature search. After that, the files of patients treated at the Cliniques universitaires Saint-Luc with those molecules will be analyzed. Finally, a concrete tool will be realized to help physicians manage drug-drug interactions when prescribing TKIs.

Drug Interactions --- Antineoplastic Agents --- Hematology --- Pharmacists --- Protein Kinase Inhibitors